Tirzepatide [30 mg]

Description

Chemical Identity & Molecular Composition

Chemical Name: Tirzepatide (LY3298176), Dual GIP and GLP-1 Receptor Agonist Peptide
Peptide Sequence: Synthetic 39-amino acid linear peptide (modified with fatty acid acylation for albumin binding)
Molecular Formula (approx.): C₂₂₀H₃₄₂N₆₂O₆₉
Molecular Weight (approx.): 4813 g/mol
Peptide Class: Dual incretin receptor agonist (GIP/GLP-1), linear acylated peptide
CAS Number: 2160873-10-4

Structural Characteristics

Tirzepatide is a synthetic linear peptide engineered to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in vitro. The peptide contains a C20 fatty diacid moiety conjugated to a lysine side chain, allowing reversible albumin binding in laboratory models, which prolongs stability and receptor interaction. Modifications to specific amino acid residues improve enzymatic resistance, solubility, and research-grade reproducibility.

Biochemical Function & Mechanistic Activity (Research Context Only)

1. Dual Receptor Activation
   In vitro studies use Tirzepatide to explore activation of GIP and GLP-1 receptors, enabling research into cAMP-mediated signaling pathways and downstream metabolic effects.

2. Enhanced Stability & Albumin Interaction
   Fatty acid acylation allows reversible binding to albumin in research systems, increasing peptide half-life and maintaining receptor engagement for extended study periods.

3. Cellular Signaling & Metabolic Pathways
   Researchers study Tirzepatide’s effects on insulinotropic signaling, beta-cell function, and nutrient-sensing pathways in controlled laboratory models.

4. Experimental Outcomes
   Tirzepatide allows laboratory investigation of dual incretin receptor pharmacology, peptide-receptor kinetics, and metabolic pathway modulation. All observations are limited to in vitro research and are not therapeutic claims.

Research Applications

Tirzepatide is commonly used in laboratory studies to investigate:

• Dual GIP and GLP-1 receptor activation and signaling

• cAMP and downstream metabolic pathways

• Peptide half-life and albumin-binding kinetics

• Beta-cell function and insulinotropic signaling in vitro

• Structure-function relationships of modified acylated peptides

• Nutrient-sensing and metabolic regulation pathways

All applications are intended strictly for non-clinical, in vitro research use only.

Product Specifications

Form & Stability
Format: Lyophilized linear acylated peptide
Purity: ≥ 98% (HPLC validated)
Appearance: White to off-white lyophilized powder
Solubility: Water-soluble; optimal in sterile laboratory buffers
Stability: Stable in lyophilized form; sensitive to moisture, light, and temperature after reconstitution

Storage
Store at –20°C
Protect from light and humidity
Avoid repeated freeze–thaw cycles
Use aseptic laboratory handling procedures

Packaging
Provided in sterile, sealed vials
Labeled with batch, lot, purity, and molecular identification
Manufactured under controlled laboratory conditions for research-grade integrity

Composition

Each vial contains:
5mg, 10mg, or 20mg of high-purity Tirzepatide (synthetic dual receptor peptide)
No fillers, additives, or excipients
Lyophilized to ensure maximum stability and reproducible research outcomes

Intended Use

This compound is intended exclusively for laboratory research, including:

• Dual incretin receptor signaling studies

• cAMP-mediated metabolic pathway research

• Beta-cell function and insulinotropic assays

• Peptide half-life and albumin-binding evaluation

• In vitro nutrient-sensing and metabolic regulation experiments

Not for human or animal consumption, medical, therapeutic, cosmetic, or diagnostic applications.

Research-Only Disclaimer

This product is strictly for research use only. It is NOT intended for:

• Human or animal consumption

• Therapeutic or cosmetic use

• Clinical or diagnostic applications

• In vivo studies

Proper laboratory handling procedures and safety protocols are required.